Ads
related to: thermo fisher cell and gene therapy approvals company- Case Studies
It’s about results, not just ideas
ZS helps clients drive growth
- Insights
Access ZS's latest insights, repor
Infographics, Articles and more
- Solutions
Get Industry Expertise & Solutions
That Work in the Real World
- Contact Us
Have a Question?
Let us Know How we can Help You
- Case Studies
Search results
Results from the WOW.Com Content Network
The acquisition of Life Technologies Corporation received conditional approval from the European Commission in November 2013. [4] The conditional requirement was the divestment of Thermo Fisher Scientific's cell culture (sera and media), magnetic beads and Dharmacon gene modulation businesses for antitrust reasons.
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus. [81] In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement with Moderna, Inc.
In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services. [ 30 ] [ 31 ] [ 32 ] In 2010, the company and Sanofi-Aventis created an outsourcing partnership, which, at the time was considered the largest between a contract ...
Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the US Food and Drug Administration (FDA). [13] The most common side effects include low levels of platelets and white blood cells, mouth sores, nausea, musculoskeletal pain, abdominal pain, vomiting, febrile ...
The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
Thermo Fisher forecast annual revenue in a range of $42.1 billion to $43.3 billion, shy of analysts' expectations of $42.93 billion at midpoint, according to LSEG data.
Patheon is a service brand within Thermo Fisher Scientific's brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging.
Ads
related to: thermo fisher cell and gene therapy approvals company